- Home
- Na Cardiac Safety Services Market
NA Cardiac Safety Services Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-480 | No of pages: 151 | Format:
North America cardiac safety services market is projected to register a CAGR of 15.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029
Market Segmentation:
North America Cardiac Safety Services Market, By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the North America cardiac safety services market are:
Growing awareness among people regarding cardiac problems and chronic heart disease
increasing research and development expenditure by the healthcare industries
Market Players:
The key market players for North America cardiac safety services market are listed below:
Koninklijke Philips N.V.
Laboratory Corporation of America Holdings
IQVIA
Medpace
Ncardia
Certara
Eurofins Scientific
SGS SA
Banook
Celerion
PhysioStim
Shanghai Medicilon Inc
Clario
PPD Inc
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 26 1.1 OBJECTIVES OF THE STUDY 26 1.2 MARKET DEFINITION 26 1.3 OVERVIEW OF NORTH AMERICA CARDIAC SAFETY SERVICES MARKET 26 1.4 LIMITATIONS 27 1.5 MARKETS COVERED 28 2 MARKET SEGMENTATION 30 2.1 MARKETS COVERED 30 2.2 GEOGRAPHICAL SCOPE 31 2.3 YEARS CONSIDERED FOR THE STUDY 32 2.4 CURRENCY AND PRICING 32 2.5 DBMR TRIPOD DATA VALIDATION MODEL 33 2.6 MULTIVARIATE MODELLING 36 2.7 SERVICES LIFELINE CURVE 36 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37 2.9 DBMR MARKET POSITION GRID 38 2.10 MARKET END USER GRID 40 2.11 VENDOR SHARE ANALYSIS 41 2.12 SECONDARY SOURCES 42 2.13 ASSUMPTIONS 42 3 EXECUTIVE SUMMARY 43 4 PREMIUM INSIGHTS 46 4.1 PORTERS FIVE FORCES 47 4.2 PESTEL ANALYSIS 48 5 EPIDEMIOLOGY 49 5.1 INCIDENCE OF ALL BY GENDER 49 5.2 TREATMENT RATE 50 5.3 MORTALITY RATE 50 5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 51 6 INDUSTRY INSIGHT 52 6.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 52 6.2 PATENT ANALYSIS 53 6.3 PATENT FLOW DIAGRAM 54 6.4 KEY PATIENT ENROLLMENT STRATEGIES 54 6.5 PRICING STRATEGY 57 7 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: REGULATIONS 58 8 MARKET OVERVIEW 61 8.1 DRIVERS 63 8.1.1 INCREASE IN THE NUMBER OF CLINICAL TRIALS 63 8.1.2 INCREASE IN HEALTHCARE EXPENDITURE AND FUNDING 63 8.1.3 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 64 8.1.4 INCREASE IN R&D ACTIVITIES 64 8.2 RESTRAINTS 65 8.2.1 HIGH COST OF CARDIAC SAFETY EVALUATION 65 8.2.2 STRICT REGULATORY 65 8.3 OPPORTUNITIES: 66 8.3.1 INCREASE IN NEW DRUG DEVELOPMENT 66 8.3.2 RISE IN THE EXPANSION OF THE CARDIAC SAFETY SERVICES 67 8.4 CHALLENGES 67 8.4.1 TIME-CONSUMING PROCEDURE 67 8.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CARDIAC SAFETY EVALUATION 68 9 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES 69 9.1 OVERVIEW 70 9.2 ECG/HOLTER MEASUREMENTS 74 9.3 BLOOD PRESSURE MEASUREMENTS 74 9.4 IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES 75 9.4.1 HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS 76 9.4.1.1 1 CONCENTRATIONS 76 9.4.1.2 4 CONCENTRATIONS 76 9.4.2 COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) 77 9.4.2.1 3 CONCENTRATIONS 77 9.4.2.2 5 CONCENTRATIONS 77 9.4.3 IN VITRO HERG ASSAY 77 9.4.4 OTHERS 77 9.5 CARDIOVASCULAR IMAGING 77 9.6 REAL TIME TELEMETRY MONITORING 78 9.7 CENTRAL OVER-READ OF ECGS 79 9.8 NON-INVASIVE CARDIAC IMAGING 79 9.9 PHYSIOLOGIC STRESS TESTING 80 9.10 THOROUGH QT STUDIES 81 9.11 TQT AND EXPOSURE RESPONSE MODELLING 81 9.12 PLATELET AGGREGATION 82 9.13 OTHERS 83 10 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY PHASE 84 10.1 OVERVIEW 85 10.2 PHASE I 88 10.3 PHASE II 88 10.4 PHASE III 89 11 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY TYPE 90 11.1 OVERVIEW 91 11.2 INTEGRATED SERVICES 94 11.3 STANDALONE SERVICES 95 12 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY END USER 96 12.1 OVERVIEW 97 12.2 PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES 100 12.3 CONTRACT RESEARCH ORGANIZATIONS 100 12.4 ACADEMIC AND RESEARCH INSTITUTE 101 13 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY REGION 102 13.1 NORTH AMERICA 103 13.1.1 U.S. 111 13.1.2 CANADA 114 13.1.3 MEXICO 117 14 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: COMPANY LANDSCAPE 120 14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 120 15 COMPANY PROFILE 121 15.1 EUROFINS SCIENTIFIC 121 15.1.1 COMPANY SNAPSHOT 121 15.1.2 REVENUE ANALYSIS 122 15.1.3 COMPANY SHARE ANALYSIS 122 15.1.4 PRODUCT PORTFOLIO 122 15.1.5 RECENT DEVELOPMENTS 123 15.1.5.1 AGREEMENTS 123 15.1.5.2 ACQUISITION 123 15.2 PPD INC. (SUBSIDIARY OF THERMO FISHER SCIENTIFIC INC) 124 15.2.1 COMPANY SNAPSHOT 124 15.2.2 REVENUE ANALYSIS 124 15.2.3 COMPANY SHARE ANALYSIS 125 15.2.4 PRODUCT PORTFOLIO 125 15.2.5 RECENT DEVELOPMENT 125 15.2.5.1 INVESTMENT 125 15.3 KONINKLIJKE PHILIPS N.V. 126 15.3.1 COMPANY SNAPSHOT 126 15.3.2 REVENUE ANALYSIS 126 15.3.3 COMPANY SHARE ANALYSIS 127 15.3.4 PRODUCT PORTFOLIO 127 15.3.5 RECENT DEVELOPMENT 127 15.3.5.1 ACQUISITION 127 15.4 IQVIA 128 15.4.1 COMPANY SNAPSHOT 128 15.4.2 REVENUE ANALYSIS 128 15.4.3 COMPANY SHARE ANALYSIS 129 15.4.4 PRODUCT PORTFOLIO 129 15.4.5 RECENT DEVELOPMENTS 129 15.4.5.1 ACQUISITION 129 15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS 130 15.5.1 COMPANY SNAPSHOT 130 15.5.2 REVENUE ANALYSIS 130 15.5.3 COMPANY SHARE ANALYSIS 131 15.5.4 PRODUCT PORTFOLIO 131 15.5.5 RECENT DEVELOPMENTS 131 15.5.5.1 NEW LABORATORY 131 15.5.5.2 ACQUISITION 131 15.6 BANOOK 132 15.6.1 COMPANY SNAPSHOT 132 15.6.2 PRODUCT PORTFOLIO 132 15.6.3 RECENT DEVELOPMENT 132 15.6.3.1 AGREEMENT 132 15.7 BIOTRIAL 133 15.7.1 COMPANY SNAPSHOT 133 15.7.2 PRODUCT PORTFOLIO 133 15.7.3 RECENT DEVELOPMENT 133 15.7.3.1 NEW CENTER OPENING 133 15.8 CELERION 134 15.8.1 COMPANY SNAPSHOT 134 15.8.2 PRODUCT PORTFOLIO 134 15.8.3 RECENT DEVELOPMENT 134 15.8.3.1 NEW CENTER OPENING 134 15.9 CERTARA 135 15.9.1 COMPANY SNAPSHOT 135 15.9.2 REVENUE ANALYSIS 135 15.9.3 PRODUCT PORTFOLIO 136 15.9.4 RECENT DEVELOPMENTS 136 15.9.4.1 CONTRACT 136 15.9.4.2 ACQUISITION 136 15.10 CLARIO 137 15.10.1 COMPANY SNAPSHOT 137 15.10.2 PRODUCT PORTFOLIO 137 15.10.3 RECENT DEVELOPMENT 137 15.10.3.1 PRODUCT EXPANSION 137 15.11 MEDPACE 138 15.11.1 COMPANY SNAPSHOT 138 15.11.2 REVENUE ANALYSIS 138 15.11.3 PRODUCT PORTFOLIO 139 15.11.4 RECENT DEVELOPMENTS 139 15.11.4.1 ACQUISITION 139 15.12 NCARDIA 140 15.12.1 COMPANY SNAPSHOT 140 15.12.2 PRODUCT PORTFOLIO 140 15.12.3 RECENT DEVELOPMENT 140 15.12.3.1 PARTNERSHIP 140 15.13 NEXEL CO., LTD 141 15.13.1 COMPANY SNAPSHOT 141 15.13.2 PRODUCT PORTFOLIO 141 15.13.3 RECENT DEVELOPMENTS 141 15.13.3.1 JOINT VENTURE 141 15.13.3.2 PARTNERSHIP 142 15.14 PHYSIOSTIM 143 15.14.1 COMPANY SNAPSHOT 143 15.14.2 PRODUCT PORTFOLIO 143 15.14.3 RECENT DEVELOPMENT 143 15.14.3.1 PARTNERSHIP 143 15.15 RICHMOND PHARMACOLOGY 144 15.15.1 COMPANY SNAPSHOT 144 15.15.2 PRODUCT PORTFOLIO 144 15.15.3 RECENT DEVELOPMENT 144 15.15.3.1 EVENT 144 15.16 SGS SA 145 15.16.1 COMPANY SNAPSHOT 145 15.16.2 REVENUE ANALYSIS 145 15.16.3 PRODUCT PORTFOLIO 146 15.16.4 RECENT DEVELOPMENT 146 15.16.4.1 ACQUISITION 146 15.17 SHANGHAI MEDICILON INC. 147 15.17.1 COMPANY SNAPSHOT 147 15.17.2 PRODUCT PORTFOLIO 147 15.17.3 RECENT DEVELOPMENTS 147 15.17.3.1 PARTNERSHIP 147 15.17.3.2 PARTNERSHIP 148 16 QUESTIONNAIRE 149 17 RELATED REPORTS 151Segmentation
Short Description North America Cardiac Safety Services Market, By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) Industry Trends and Forecast to 2029 Market Definition: Cardiac safety services generally help support and design clinical trials and other research needed to monitor heart safety. The demand for cardiac safety services market has been increased in both developed well as in developing countries and the reason behind this is the increasing number of clinical trials and product launch. The cardiac safety services market is growing due to introduction of innovative products, increasing in technological products and rising disposable income. The market will grow in forecasted period due to exploration of emerging markets, strategic initiatives by market players, increasing healthcare expenditure. Market Segmentation: The cardiac safety services market is categorized into four notable segment which is services, type, phase and end user. On the basis of services, the cardiac safety services market is segmented into ECG/Holter measurements, blood pressure measurements, in vitro cardiac safety assessment services, cardiovascular imaging, real-time telemetry monitoring, central over-read of ECGS, non-invasive cardiac imaging, physiologic stress testing, thorough QT studies, TQT and exposure response modeling, platelet aggregation and other services. On the basis of phases, the cardiac safety services market is segmented into phase 1, phase 2 and phase 3. In 2022, phase 1 is expected to dominate the global cardiac safety services market with the increasing new drug development and rising strategic initiatives by major market players. On the basis of type, the cardiac safety services market is segmented into integrated services and standalone services. In 2022, integrated services is expected to dominate the global cardiac safety services market with the increasing advanced technology and rising healthcare expenditure. On the basis of end user, the cardiac safety services market is segmented pharmaceuticals & biopharmaceuticals companies, contract research organizations and academic and research institute. In 2022, hospital is expected to dominate the global cardiac safety services market with the increasing number of patients and surgeries. Market Players The key market players for North America cardiac safety services market are listed below: Koninklijke Philips N.V. Laboratory Corporation of America Holdings IQVIA Medpace Ncardia Certara Eurofins Scientific SGS SA Banook Celerion PhysioStim Shanghai Medicilon Inc Clario PPD IncMethodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.